Research

The Centre for Advanced studies in Biomedical Innovation Law explores the legal challenges and the rapid developments in the biotechnological area. The centre brings together scholars from the worlds leading research institutions in interdisciplinary collaboration also engaging stakeholders from industry, government and civil society.

Research programs

• AI@Care: Law and Ethics and Algorithmic Bias in Healthcare

  AI@CARE conceptualizes and computationally models how bias and discrimination occur within medical artificial intelligence.

• CeBIL- Collaborative Research program in Biomedical Innovation Law

  Interdisciplinary research program that will focus on innovation inefficiencies on the Life Science Frontiers.

• Global IPR and Life Sciences

  In a series of webinars commencing in 2021 international experts and stakeholders will debate challenges facing Global IPR and Life Sciences.

• Reconceptualising Reproductive Rights

  This project seeks to theorize and reconceptualize reproductive rights, and through this contribute to legal theory about reproductive rights.

• Regulation of Patient Centered Clinical Trials (REPACT)

  REPACT is a three-year research collaboration between CeBIL and the Danish Medicines Agency’s Data Analytics Center (DAC).

• RESPOND³ - Responsible early Digital Drug Discovery

  We aim to find new antibiotics and therapies for Chronic Obstructive Pulmonary Disease through the development of improved high-throughput computational methods.

• Technologies of Death and Dying at the Beginning of Life

  TechnoDeath will set a new research agenda contributing to reproductive and death studies with new humanities perspectives.

• ICE AGE - Entangled Lives, Times and Ethics in Fertility Preservation

  We will seek develop cultural theories on reproductive time, and enable scholarly-grounded public policies, debates, and law on fertility preservation.

• JURFAST - A new legal framework for health data

  The research will provide a comprehensive, systematized and easily accessible analysis of the rules on the use of health data for research.

• Reinterpreting TRIPS in the life sciences

  In a series of webinars in 2017 and 2018 international experts set focus on the TRIPS agreement and the life sciences.